PIK3CA and follicular lymphoma: Copanlisib, a pan-class I PI3K inhibitor, was approved by the FDA in 2017 for relapsed follicular lymphoma but was later withdrawn after the Phase III CHRONOS-4 trial failed to show additional benefit over immunochemotherapy [52, 53].